| General Information | |
|---|---|
| ZINC ID | ZINC000043100770 |
| Molecular Weight (Da) | 482 |
| SMILES | CSc1c(C(=O)NN2CCCC2)nc(-c2ccc(Cl)cc2Cl)n1-c1ccc(Cl)cc1 |
| Molecular Formula | C21Cl3N4O1S1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 124.24 |
| HBA | 3 |
| HBD | 1 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 30 |
| LogP | 6.532 |
| Activity (Ki) in nM | 3.1623 |
| Polar Surface Area (PSA) | 75.46 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.837 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 17 |
| Fraction csp3 | 0.24 |
| Ilogp | 4.2 |
| Xlogp3 | 6.39 |
| Wlogp | 5.58 |
| Mlogp | 5 |
| Silicos-it log p | 4.93 |
| Consensus log p | 5.22 |
| Esol log s | -6.88 |
| Esol solubility (mg/ml) | 0.0000641 |
| Esol solubility (mol/l) | 0.00000013 |
| Esol class | Poorly sol |
| Ali log s | -7.77 |
| Ali solubility (mg/ml) | 0.00000824 |
| Ali solubility (mol/l) | 1.71E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.08 |
| Silicos-it solubility (mg/ml) | 0.00000403 |
| Silicos-it solubility (mol/l) | 8.36E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.7 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.48 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.748 |
| Logd | 4.485 |
| Logp | 5.103 |
| F (20%) | 0.001 |
| F (30%) | 0.003 |
| Mdck | - |
| Ppb | 99.44% |
| Vdss | 0.396 |
| Fu | 1.23% |
| Cyp1a2-inh | 0.605 |
| Cyp1a2-sub | 0.699 |
| Cyp2c19-inh | 0.815 |
| Cyp2c19-sub | 0.634 |
| Cl | 3.352 |
| T12 | 0.036 |
| H-ht | 0.681 |
| Dili | 0.957 |
| Roa | 0.251 |
| Fdamdd | 0.916 |
| Skinsen | 0.047 |
| Ec | 0.003 |
| Ei | 0.011 |
| Respiratory | 0.649 |
| Bcf | 2.658 |
| Igc50 | 4.789 |
| Lc50 | 5.943 |
| Lc50dm | 6.145 |
| Nr-ar | 0.012 |
| Nr-ar-lbd | 0.009 |
| Nr-ahr | 0.909 |
| Nr-aromatase | 0.932 |
| Nr-er | 0.753 |
| Nr-er-lbd | 0.011 |
| Nr-ppar-gamma | 0.171 |
| Sr-are | 0.919 |
| Sr-atad5 | 0.162 |
| Sr-hse | 0.482 |
| Sr-mmp | 0.936 |
| Sr-p53 | 0.924 |
| Vol | 430.738 |
| Dense | 1.114 |
| Flex | 0.261 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 2 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 1 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.457 |
| Synth | 2.691 |
| Fsp3 | 0.238 |
| Mce-18 | 53.077 |
| Natural product-likeness | -1.401 |
| Alarm nmr | 2 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |